September 2022
-
Media ReleasePhilippine FDA approves Novartis drug, ribociclib, for advanced breast cancer in malesThe Philippine Food and Drug Administration (FDA) has approved ribociclib for the treatment of metastatic breast cancer. Ribociclib in combination with an aromatase inhibitor or fulvestrant can be…
-
Story
Novartis supports the Southeast Asian Breast Cancer Symposium
August 2022
-
Media ReleaseAlliance and Partnerships for Patient Innovation and Solutions (APPIS) Initiative announces winners of inaugural Innovator ProgramThe APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support, networking…
-
Media ReleaseNovartis hails Philippine FDA approval of brolucizumab treatment for age-related macular degeneration in time for Sight Saving MonthThe Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…
July 2022
-
Media ReleaseNovartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy lifePsoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help their…
-
Media ReleaseExperts encourage women with advanced breast cancer to get tested for PIK3CA mutation to improve treatment outcomesGenetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized…
-
Media ReleasePhilippine FDA approves Novartis advanced breast cancer treatment, alpelisibThe Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…
May 2022
-
Media ReleaseNovartis Philippines launches PIK3CA Testing Program for Breast CancerStakeholder officials signed the formal agreement to implement the Novartis PIK3CA Testing Program for advanced Breast Cancer patients. Photo shows (from left): Ms.…
-
Media ReleaseSurvey reveals delayed diagnosis, heavy disease burden among Filipinos with axial spondyloarthritisOn average, Filipinos with axial spondyloarthritis (axSpA) are diagnosed 5.8 years after developing the disease. axSpA has significant functional, psychosocial and economic impact on patients,…
February 2022
-
Media ReleaseWorld Cancer Day 2022: Novartis committed to helping close the gap in cancer careIn observance of World Cancer Day, Novartis reiterated its commitment to enhancing access to innovative cancer treatments. World Cancer Day is observed on February 4 of every year. Its theme for…
-
Story Education & Awareness
Asia Pacific Patient Innovation Summit: Philippines Outcome Report 2021